Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 19/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 0.86 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517373 | 0.95 | PTK2 (1.00) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL22658378 | 0.95 | PTK2 (1.00) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL29517224 | 0.94 | PTK2 (1.00) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL29767861 | 0.92 | PTK2 (1.00) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL29767867 | 0.92 | PTK2 (1.00) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL22658775 | 0.90 | PTK2 (0.94) | PTK2PLK1LRRK2 | |
| SCHEMBL29517311 | 0.90 | PTK2 (0.94) | PTK2PLK1LRRK2 | |
| SCHEMBL22658865 | 0.87 | PTK2 (0.85) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL29517755 | 0.86 | PTK2 (1.00) | PTK2PLK1MAPK7LRRK2 | |
| SCHEMBL29517325 | 0.86 | PTK2 (1.00) | PTK2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3965803-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231726-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | PTK2 1/4885PLK1 51/4885MAPK7 706/4885 |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | PTK2, CTTN, TNK2 | PTK2 1/4885PLK1 51/4885MAPK7 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.